Board of Directors

Dimitri F Dimitriou, MSc
Chief Executive Officer

Dr Robert Zimmer, MD, PhD
President & Chief Science Officer

Dr Franco Di Muzio
Senior Non-Executive Director

Dr Ajay Agrawal, PhD
Non-Executive Director

Tracy Weimar
Vice President, Operations & Finance
Company Secretary

Please click on the name of the members to view a brief biography

Committees

An Audit Committee and a Remuneration Committee have been established with formally delegated duties and responsibilities. The members of both committees are the non executive Directors.

Audit Committee
The Audit Committee which determines the engagement of the Company’s auditors and, in consultation with them, the scope of their audit. The Audit Committee receives and reviews reports from management and the auditors relating to the interim and annual accounts and the accounting and internal control systems in use by the company. It has unrestricted access to the auditors. The Board and the Audit Committee review the need for an internal audit function on an annual basis and currently do not consider it to be necessary at this stage in the Company’s development. The Directors acknowledge their responsibilities for the Group’s system of internal financial controls. They have not, during the period ended 31st December 2006, carried out a formal annual review of internal financial controls in view of the small size of the Board and employees. The Group’s financial reporting arrangements are designed to provide the Directors with reasonable assurance that problems are identified on a timely basis and dealt with appropriately. The Board considers that the business is a going concern, having reviewed anticipated future expenditure in the context of available cash balances.

Remuneration Committee
The Remuneration Committee reviews the scale and structure of the executive Directors’ remuneration and benefits and the terms of their service contracts. The remuneration of the non-executive directors is determined by the Board as a whole. The committee has formal terms of reference and meets at least twice a year. It is the duty of the committee, inter alia, to determine and agree with the Board the framework or broad policy for the remuneration of the Company’s executive board members. This policy is currently being developed but the remuneration package for executive directors will comprise basic salary, pension contribution, annual bonus and share options. The remuneration packages are designed to motivate and retain Executive Directors to ensure the continuing development of the company and to reward them for enhancing value to shareholders.


Home About ImmuPharma Lead compounds Discovery pipeline Management team News For Investors Contact us	Board of Directors Richard Warr, MA Chairman Dimitri F Dimitriou, MSc Chief Executive Officer Dr Robert Zimmer, MD, PhD President & Chief Science Officer Dr Franco Di Muzio Senior Non-Executive Director Dr Ajay Agrawal, PhD Non-Executive Director Tracy Weimar Vice President, Operations & Finance Company Secretary Please click on the name of the members to view a brief biography Committees An Audit Committee and a Remuneration Committee have been established with formally delegated duties and responsibilities. The members of both committees are the non executive Directors. Audit Committee The Audit Committee which determines the engagement of the Company’s auditors and, in consultation with them, the scope of their audit. The Audit Committee receives and reviews reports from management and the auditors relating to the interim and annual accounts and the accounting and internal control systems in use by the company. It has unrestricted access to the auditors. The Board and the Audit Committee review the need for an internal audit function on an annual basis and currently do not consider it to be necessary at this stage in the Company’s development. The Directors acknowledge their responsibilities for the Group’s system of internal financial controls. They have not, during the period ended 31st December 2006, carried out a formal annual review of internal financial controls in view of the small size of the Board and employees. The Group’s financial reporting arrangements are designed to provide the Directors with reasonable assurance that problems are identified on a timely basis and dealt with appropriately. The Board considers that the business is a going concern, having reviewed anticipated future expenditure in the context of available cash balances. Remuneration Committee The Remuneration Committee reviews the scale and structure of the executive Directors’ remuneration and benefits and the terms of their service contracts. The remuneration of the non-executive directors is determined by the Board as a whole. The committee has formal terms of reference and meets at least twice a year. It is the duty of the committee, inter alia, to determine and agree with the Board the framework or broad policy for the remuneration of the Company’s executive board members. This policy is currently being developed but the remuneration package for executive directors will comprise basic salary, pension contribution, annual bonus and share options. The remuneration packages are designed to motivate and retain Executive Directors to ensure the continuing development of the company and to reward them for enhancing value to shareholders.